Topic: proteomics

Vividion Therapeutics

Vividion Therapeutics seeks to deploy its synthetic and proteomic chemistry platforms to “dramatically expand” the number of targets that can be approached therapeutically. Its technology identifies previously unknown druggable targets in the human proteome.